Provided by Tiger Trade Technology Pte. Ltd.

Clearmind Medicine, Inc.

1.17
-0.0700-5.65%
Post-market: 1.220.0542+4.63%19:59 EST
Volume:16.62K
Turnover:19.66K
Market Cap:1.75M
PE:-0.04
High:1.23
Open:1.23
Low:1.15
Close:1.24
52wk High:53.70
52wk Low:1.05
Shares:1.50M
Float Shares:1.25M
Volume Ratio:0.29
T/O Rate:1.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-30.3500
EPS(LYR):-30.3477
ROE:-179.39%
ROA:-53.11%
PB:1.47
PE(LYR):-0.04

Loading ...

Clearmind Medicine Reports Progress on MEAI as Next-Generation Weight Loss Therapy Market Shifts Beyond GLP-1 Drugs

Reuters
·
Feb 20

Clearmind Medicine files to sell 8.17M common shares for holders

TIPRANKS
·
Feb 18

Psychedelic: Clearmind reports additional CMND-100 safety results

TIPRANKS
·
Feb 12

BRIEF-Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile Of Cmnd-100 In Ongoing Phase I/Iia Clinical Trial

Reuters
·
Feb 09

Clearmind Medicine Reports Positive Safety Results for CMND-100 in Alcohol Use Disorder Trial

Reuters
·
Feb 09

Clearmind Medicine Inc - Safety Data Show No Serious Adverse Events in Second Cohort

THOMSON REUTERS
·
Feb 09

Clearmind Medicine Inc - Announces Positive Safety Results From Phase I/Iia Trial

THOMSON REUTERS
·
Feb 09

Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial

GlobeNewswire
·
Feb 09

BRIEF-Clearmind Medicine Enters Development Agreement For Intranasal Formulation Of Proprietary Nonhallucinogenic Neuroplastogen MEAI

Reuters
·
Feb 06

BUZZ-Polyrizon jumps as it teams up with Clearmind for intranasal drug delivery

Reuters
·
Feb 06

Clearmind Medicine Enters Into Development Agreement to Advance Intranasal Formulation for Its Proprietary Non-Hallucinogenic Neuroplastogen Meai

THOMSON REUTERS
·
Feb 06

Polyrizon Partners with Clearmind to Develop Intranasal MEAI Formulation

Reuters
·
Feb 06

Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation

THOMSON REUTERS
·
Feb 06

Clearmind Medicine Issues $2.5 Million in Convertible Promissory Notes

Reuters
·
Feb 05

Clearmind Medicine gibt Ausgabe von Wandelanleihen im Gesamtwert von 2,5 Millionen US-Dollar bekannt

Reuters
·
Feb 05

Clearmind Medicine welcomes inclusion of MEAI in bipartisan legislation

TIPRANKS
·
Feb 03

Clearmind Medicine erzielt Durchbruch mit MEAI in US-Gesetz für innovative Veteranen-Therapien

Reuters
·
Feb 03

Psychedelic: Clearmind completes second cohort treatment for CMND-100 trial

TIPRANKS
·
Jan 15

BRIEF-Clearmind Medicine Inc - Topline Results From Second Cohort Of CMND-100 Expected In Coming Months

Reuters
·
Jan 14

Clearmind Medicine Inc - Topline Results From Second Cohort of Cmnd-100 Expected in Coming Months

THOMSON REUTERS
·
Jan 14